Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36

Blood

Volumn 119, Issue 25, 2012, Pages 6136-6144

  Zhu, Weifei ^a   Li, Wei ^a,b   Silverstein, Roy L ^c,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CD36 ANTIGEN; STREPTOZOCIN; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; THROMBOCYTE; THROMBOSIS;

EID: 84862748475     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-387506     Document Type: Article

References (43)

1. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011; 117(22):5857-5859.
2. Franchini M, Targher G, Montagnana M, Lippi G. The metabolic syndrome and the risk of arterial and venous thrombosis. Thromb Res. 2008; 122(6):727-735.
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-234. (Pubitemid 28350165)
4. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108(12):1527-1532. (Pubitemid 37176462)
5. Ferreiro JL, Gómez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res. 2010;7(4):251-259.
6. Garraud O, Cognasse F. Platelet Toll-like receptor expression: the link between "danger" ligands and inflammation. Inflamm Allergy Drug Targets. 2010;9(5):322-333.
7. Ghosh A, Murugesan G, Chen K, et al. Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms. Blood. 2011;117(23):6355-6366.
8. Chen K, LiW, Major J, Rahaman SO, Febbraio M, Silverstein RL. Vav guanine nucleotide exchange factors link hyperlipidemia and a prothrombotic state. Blood. 2011;117(21):5744-5750.
9. Podrez EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13(9): 1086-1095. (Pubitemid 47517507)
10. Chen K, Febbraio M, Li W, Silverstein RL. A specific CD36-dependent signaling pathway is required for platelet activation by oxidized lowdensity lipoprotein. Circ Res. 2008;102(12):1512-1519.
11. Ghosh A, Li W, Febbraio M, et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest. 2008;118(5):1934-1943. (Pubitemid 351632395)
12. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058-1070.
13. Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y. Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract. 1998;41(2):131-137. (Pubitemid 28459016)
14. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318(20):1315-1321.
15. Ohgami N, Nagai R, Ikemoto M, et al. CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products. Ann N Y Acad Sci. 2001;947:350-355. (Pubitemid 34059934)
16. Hasegawa Y, Suehiro A, Higasa S, Namba M, Kakishita E. Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus. Thromb Res. 2002;107(6):319-323. (Pubitemid 36139885)
17. Sobol AB,Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract. 2000;50(1):1-16. (Pubitemid 30629015)
18. Han Y, Liu Y, Mi Q, et al. Pyridoxine improves platelet nitric oxide synthase dysfunction induced by advanced glycation end products in vitro. Int J Vitam Nutr Res. 2010;80(3):168-177.
19. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103(11):1547-1560.
20. LiW, Febbraio M, Reddy SP, Yu DY, Yamamoto M, Silverstein RL. CD36 participates in a signaling pathway that regulates ROS formation in murine VSMCs. J Clin Invest. 2010;120(11):3996-4006.
21. Podrez EA, Poliakov E, Shen Z, et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem. 2002;277(41): 38503-38516. (Pubitemid 35154709)
22. Ranzato E, Patrone M, Pedrazzi M, Burlando B. Hmgb1 promotes wound healing of 3T3 mouse fibroblasts via RAGE-dependent ERK1/2 activation. Cell Biochem Biophys. 2010;57(1):9-17.
23. Eckel RH, Wassef M, Chait A, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation. 2002;105(18): e138-e143.
24. Lüscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation. 2003;108(13):1655-1661. (Pubitemid 37187795)
25. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482-2494.
26. Winocour PD, Watala C, Perry DW, Kinlough-Rathbone RL. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost. 1992; 68(5):577-582.
27. Watala C, Golański J, Boncler MA, Pietrucha T, Gwoździński K. Membrane lipid fluidity of blood platelets: a common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood. Platelets. 1998; 9(5):315-327. (Pubitemid 28473167)
28. Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol. 2003;92(11):1362-1365. (Pubitemid 37431156)
29. Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, PfeifferAF. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia. 2001;44(2):188-195. (Pubitemid 32156203)
30. Ferretti G, Rabini RA, Bacchetti T, et al. Glycated low density lipoproteins modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab. 2002;87(5):2180-2184. (Pubitemid 34521506)
31. Chen L, Liu Y, Cui B, et al. 17Beta-oestradiol partially attenuates the inhibition of nitric oxide synthase-3 by advanced glycation end-products in human platelets. Clin Exp Pharmacol Physiol. 2007;34(10):972-978. (Pubitemid 47274552)
32. Hangaishi M, Taguchi J, Miyata T, et al. Increased aggregation of human platelets produced by advanced glycation end products in vitro. Biochem Biophys Res Commun. 1998; 248(2):285-292. (Pubitemid 28386414)
33. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108(7):949-955. (Pubitemid 32946067)
34. Schmidt AM, Stern DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab. 2000;11(9):368-375.
35. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267(21):14998-15004.
36. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem. 1997;272(26):16498-16506. (Pubitemid 27276477)
37. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res. 2010; 106(5):842-853.
38. Yang Z, Makita Z, Horii Y, et al. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med. 1991;174(3):515-524.
39. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev. 2001;17(6):436-443. (Pubitemid 34030746)
40. Ohgami N, Nagai R, Ikemoto M, et al. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem. 2001;276(5):3195-3202.
41. Horiuchi S, Unno Y, Usui H, et al. Pathological roles of advanced glycation end product receptors SR-A and CD36. Ann N Y Acad Sci. 2005; 1043:671-675. (Pubitemid 41123958)
42. Yamagishi S, Matsui T, Takenaka K, Nakamura K, Takeuchi M, Inoue H. Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs). Diabetes Metab Res Rev. 2009;25(3):266-271.
43. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123(7):798-813.